of comorbid conditions, interventions Diagnosis and treatment, treatment reduction of risk factors for CVD to slow disease progression,

Similar documents
Hematology TOONYA TURNER. IDEXX Services: Senior Profile with Heartworm -Standard CBC. RBC M/µL. Hematocrit

Impact of left ventricular hypertrophy on survival in end-stage renal disease

High incidence of vertebral osteoporotic fracture within the first year after liver transplantation

Safety and Tolerability of Subcutaneous Sarilumab and Intravenous Tocilizumab in Patients With RA

Bright Futures Medical Screening Reference Table 2 to 5 Day (First Week) Visit

Anemia in pediatric hemodialysis patients: Results from the 2001 ESRD Clinical Performance Measures Project

CME/SAM. Study on Hyperuricemia in HBV-Associated Glomerulonephritis

CHARLIE HASSID. Hematocrit SDMA WBC ALT. Creatinine BUN ALP. Hematology. Species: Canine Gender: Male Year of Birth: 2005 Client: HASSID

PAQUITO RAMIREZ RAMIREZ

Risks for All-Cause Mortality: Stratified by Age, Estimated Glomerular Filtration Rate and Albuminuria

ABC Fax Original Paper

Incidence of proteinuria in type 2 diabetes mellitus in the Pima Indians

Bone mineral density is not diminished by mild to moderate

Results of improvement in adequacy of intermittent hemodialysis in uremic patients

Target: 10 mg/day within several days Schizophrenia in adolescents (2.1)

Original Paper. Med Princ Pract 2017;26: DOI: /

PNEUMOVAX 23 is recommended by the CDC for all your appropriate adult patients at increased risk for pneumococcal disease 1,2 :

DOSAGE FORMS AND STRENGTHS HIGHLIGHTS OF PRESCRIBING INFORMATION

EVALUATION OF DIFFERENT COPPER SOURCES AS A GROWTH PROMOTER IN SWINE FINISHING DIETS 1

XALKORI (crizotinib) Is Available Through Specialty Pharmacies

The RUTHERFORD-2 trial in heterozygous FH: Results and implications

Supplementary Online Content

First-line and Maintenance Treatment with ALIMTA therapy for advanced nonsquamous non-small cell lung cancer (NSCLC)

YERVOY (ipilimumab) injection, for intravenous use Initial U.S. Approval: 2011

A cross-sectional and follow-up study of leukopenia in tuberculosis patients: prevalence, risk factors and impact of anti-tuberculosis

Phosphate Salivary Secretion in Hemodialysis Patients: Implications for the Treatment of Hyperphosphatemia

Start ORKAMBI today. INDICATIONS AND USAGE IMPORTANT SAFETY INFORMATION. Sydney Age 4

obesità nel bambino: epidemiologia e prevenzione

SAN DIEGO BAY ANIMAL HOSPITAL 3681 SPORTS ARENA BLVD SAN DIEGO, CA ACCOUNT #: 6563 ATTENDING VET: STAFF,STAFF H H.

See 17 for PATIENT COUNSELING INFORMATION and FDAapproved

Assessment of Depression in Multiple Sclerosis. Validity of Including Somatic Items on the Beck Depression Inventory II

Gemmis Injection 38 mg/ml

Original Article Clinical Care/Education INTRODUCTION DIABETES & METABOLISM JOURNAL

Addendum to the Evidence Review Group Report on Aripiprazole for the treatment of schizophrenia in adolescents (aged years)

A review of the patterns of docetaxel use for hormone-resistant prostate cancer at the Princess Margaret Hospital

Supplementary Online Content

For Adults With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)

Metabolic Syndrome and Health-related Quality of Life in Obese Individuals Seeking Weight Reduction

Clinical Study Report Synopsis Drug Substance Naloxegol Study Code D3820C00018 Edition Number 1 Date 01 February 2013 EudraCT Number

Effect on Glycemic, Blood Pressure, and Lipid Control according to Education Types

XII. HIV/AIDS. Knowledge about HIV Transmission and Misconceptions about HIV

Early steroid withdrawal in a renal transplant cohort treated with tacrolimus, mycophenolate mofetil and basiliximab

Baroreceptor Activity in Normotensive and Hypertensive Uremic Patients

Table W in S1 File. Tentative breed-specific reference intervals for the Cavalier King Charles Spaniels

Seasonal influenza vaccination programme country profile: Ireland

Analysis of alternatives for insulinizing patients to achieve glycemic control and avoid accompanying risks of hypoglycemia

HIGHLIGHTS OF PRESCRIBING INFORMATION

Body mass index, waist-to-hip ratio, and metabolic syndrome as predictors of middle-aged men's health

T.S. Kurki a, *,U.Häkkinen b, J. Lauharanta c,j.rämö d, M. Leijala c

10-15 mg/day 15 mg/day 30 mg/day. 2-5 mg/day 5-10 mg/day 15 mg/day. 2 mg/day 5-10 mg/day 15 mg/day. 30 mg/day injected IM

Patient Monitoring Checklist

See 17 for PATIENT COUNSELING INFORMATION. Revised: 02/2011 FULL PRESCRIBING INFORMATION: CONTENTS*

Summary of Package Insert 1

See 17 for PATIENT COUNSELING INFORMATION and FDAapproved. Revised: 01/2019

Plasma concentrations of adrenomedullin and natriuretic peptides in patients with essential hypertension

Revised: 6/2018 History of severe hypersensitivity reaction to pemetrexed. (4)

See 17 for PATIENT COUNSELING INFORMATION and FDAapproved patient labeling. Revised: 6/2016 FULL PRESCRIBING INFORMATION: CONTENTS*

Immune-Mediated Adverse Reactions Management Guide

Results of the Tokyo Consensus Meeting Tokyo Guidelines

Urinary Tract Infection in Women

Sample content. Australian Medicines Handbook Pty Ltd

A nemia of chronic renal failure is a well-established entity, and depending on the primary renal disease, may vary in its severity ( 1 ).

Positive Heparin-Platelet Factor 4 Antibody Complex and Cardiac Surgical Outcomes

INVEGA SUSTENNA (paliperidone palmitate) extended-release injectable

Positive association between plasma homocysteine level and chronic kidney disease

For Adults with Metastatic Melanoma

Serum Potassium Levels and Mortality in Hemodialysis Patients: A Retrospective Cohort Study

Relationship between serum irisin, glycemic indices, and renal function in type 2 diabetic patients

Invasive Pneumococcal Disease Quarterly Report. July September 2017

Influence of the Duration of Diabetes on the Outcome of a Diabetes Self-Management Education Program

A Comparison of Serum Magnesium Level in Pregnant Women with and without Gestational Diabetes Mellitus (GDM)

EFFECTS OF INGREDIENT AND WHOLE DIET IRRADIATION ON NURSERY PIG PERFORMANCE

Community. Profile Powell County. Public Health and Safety Division

Community. Profile Big Horn County. Public Health and Safety Division

phosphatase isoenzyme activity: estimation of

Community. Profile Yellowstone County. Public Health and Safety Division

Community. Profile Lewis & Clark County. Public Health and Safety Division

Community. Profile Missoula County. Public Health and Safety Division

Diabetologia 9 Springer-Verlag 1985

Community. Profile Anaconda- Deer Lodge County. Public Health and Safety Division

Efficacy of Pembrolizumab in Patients With Advanced Melanoma With Stable Brain Metastases at Baseline: A Pooled Retrospective Analysis

Comparison of three simple methods for the

Community. Profile Carter County. Public Health and Safety Division

Association between orthodontic treatment and periodontal diseases: Results from a national survey

Blood pressure and diurnal variation in sodium, potassium, and water excretion

CLINICAL PRACTICE GUIDELINE

Impact of Pharmacist Intervention on Diabetes Patients in an Ambulatory Setting

Lipid-Lowering Agents

Invasive Pneumococcal Disease Quarterly Report July September 2018

Red cell distribution width and risk of peripheral artery disease: Analysis of National Health and Nutrition Examination Survey

Pharmacokinetics of Single-Dose Oral Ciprofloxacin in Patients Undergoing Chronic Ambulatory Peritoneal Dialysis

Predictors of Hospitalization in Male Marine Corps Recruits with Exertional Heat Illness

Muhammad Shoaib, Muhammad Usman, Rabia Fatima, Sajid Aziz, Muhammad Wasif Malik, Muhammad Javaid Asad and Sikandar Khan Sherwani

The Effects of Small Sized Rice Bowl on Carbohydrate Intake and Dietary Patterns in Women with Type 2 Diabetes

Metformin and breast cancer stage at diagnosis: a population-based study

BENIGN ulceration along the greater curvature of the pars media of the

European Journal of Internal Medicine

Mechanisms of autonomic nervous system dysfunction in uremia

Transcription:

Tble 5.1. NKF Clssifiction of Chronic Kidney Disese nd Clinicl Fetures Stge Description GFR (ml/ min/1.73 m 2 ) U.S. Prevlence, b # Affected (%) Clinicl Fetures Action Pln c At incresed risk for CKD >60 (with risk fctors for CKD) d DM, utoimmune diseses, systemic infections, drug exposure, neoplsi, fmily history, HTN Screening, reduction of risk fctors for CKD 1 Kidney dmge with norml or elevted GFR 2 Kidney dmge with mildly decresed GFR 90 5.9 million (3.3) Micro-lbuminuri (DM 5 10 yers, retinopthy, rising blood pressure), lbuminuri (DM 10 15 yers, retinopthy, HTN), cysts, proteinuri, + RBCs, ± WBCs, ± hydronephrosis Dignosis nd tretment, tretment of comorbid conditions, interventions to slow disese progression, reduction of risk fctors for CVD 60 89 5.3 million (3.0) Estimtion of disese progression 3 Modertely decresed GFR 4 Severely decresed GFR 30 59 7.6 million (4.3) DM, HTN, CVD, DM complictions (retinopthy), HTN complictions Evlution nd tretment of disese complictions 15 29 400,000 (0.2) Preprtion for kidney replcement therpy (dilysis, trnsplnttion) 5 Kidney filure <15 (or dilysis) 300,000 (0.1) DM, DM complictions (retinopthy), CVD, uremi Kidney replcement therpy if uremi is present For stges 1 nd 2, kidney dmge ws estimted by rtio of greter thn 17 mg of lbumin to 1 g of cretinine in men or greter thn 25 mg of lbumin to 1 g of cretinine in women on two untimed (spot) urine tests. Prevlence ge 20 for stges 1 through 4 re bsed on dt obtined from the Third Ntionl Helth nd Nutrition Exmintion Survey (1988 1994) (Sources: Jones CA et l. Am J Kidney Dis 1988;32(6):992 9; for stge 5, from the U.S. Renl Dt Survey, NIDDK, 1998). b Includes ctions from preceding stges. Prevlence of persons t incresed risk for CKD hs not been estimted ccurtely. NKF, Ntionl Kidney Foundtion; GFR, glomerulr filtrtion rte; CVD, crdiovsculr disese; HTN, hypertension; DM, dibetes mellitus; RBCs, red blood cells; WBCs, white blood cells. d CKD, chronic kidney disese; defined s either kidney dmge or GFR <60 ml per minute per 1.73 m 2 for 3 months. Kidney dmge is defined s pthologicl bnormlities or mrkers of dmge, including bnormlities in blood or urine tests or imging studies. Adpted from the Ntionl Kidney Foundtion. Am J Kidney Dis 2002;39(Suppl. 1):S1 S266. c

Tble 5.2. Serum Chemistry Lbortory Chnges in Chronic Kidney Disese (CKD) Lbortory Test Norml Rnge Norml Vlues in CKD Signs/Symptoms of Abnormlity Serum cretinine 0.7 1.4 mg/dl Incresed generlly 12 20 mg/dl (depends on muscle mss) Ftigue, dehydrtion, mentl confusion, shortness of breth Blood ure nitrogen (BUN) 7 21 mg/dl Incresed but <100 mg/dl (depends on protein intke) Ftigue, insomni, nuse, dry or itching skin, urine-like body odor nd breth Cretinine clernce 85 150 ml/min <10 ml/min Serum clcium (C ++ ) 8.5 10.5 mg/dl Sme but gol is <10 Low: ctrcts, depression, hir loss, muscle twitching/ crmping, seizures High: ftigue, muscle wekness, mentl chnges, thirst Serum phosphorus (PO4) 2.5 4.5 mg/dl Incresed but gol 3.5 5.5 mg/dl High: cuses elevted PTH by lowering C ++, bone frctures Serum sodium (N + ) 135 145 mmol/l Sme decresed Thirst resulting in drinking more with fluid gin, elevted blood pressure, shortness of breth Serum potssium (K + ) 3.6 5.0 meq/l Sme incresed but <6.0 meq/l Few until >7 meq/l, then wekness preceding crdic rrest Serum chloride (Cl ) 95 108 meq/l Sme Low: hyperexcitble nervous system, low blood pressure, shllow brething, tetny High: deep brething, ftigue, muscle wekness Serum lbumin 3.5 5.0 g/dl Gol >4.0 g/dl Weight loss, poor ppetite, mediction side effects Prthyroid hormone level (PTH) 10 65 pg/ml Stge 3; 35 70 pg/ml Erly: symptomtic Stge 4; 70 110 pg/ml Lte: itching, bony chnges on X-ry, frctures Stge 5; 150 300 pg/ml Modified from Dilysis Lb Tests t Glnce. Avilble t: http://www.esrdnetworks.org.

Tble 5.3. Trnsplnttion Immunosuppressnt Medictions Mediction Action Orl Side Effects/Dentlly Relevnt Toxicities Glucocorticoids Glucocorticoid receptor gonists, receptorindependent effects Angioedem, moon fce, orl cndidisis nd orl herpes simplex virus, nemi, neutropeni, possible drenl suppression Cyclosporine Clcineurin inhibitor Gingivl overgrowth Tcrolimus Clcineurin inhibitor Gingivl overgrowth (lower incidence thn cyclosporine) Sirolimus, everolimus Trget of rpmycin inhibitors Mouth ulcers, delyed wound heling, thrombocytopeni Mycophenolte mofetil Purine synthesis inhibitor Neutropeni, mild nemi Azthioprine Antimetbolite Leukopeni, bone mrrow depression Dclizumb, bsiliximb Anti-CD25 ntibody Rre mouth ulcers, orl cndidisis, gingivl overgrowth, thrombocytopeni Horse or rbbit ntithymocyte globulin Polyclonl ntithymocyte globulin Thrombocytopeni, leukopeni Adpted from Hllorhn PF. N Engl J Med 2004;351(26): 2715 29.

Tble 5.4. Dentlly Prescribed Mediction Adjustment for Ptients with Kidney Disese Adjustment of Mintennce Dose Intervls (in Hours), Totl Dose, or Timing with Dilysis for Adult Ptients in Renl Filure Drug Usul Dosge Norml Renl Function Mild Renl Filure (GRF > 50) Moderte Renl Filure (GRF 10 50) Severe Renl Filure (GRF < 10) Hemodilysis (HD) Peritonel Dilysis Antibiotics Amoxicillin 250 500 mg q8 8 8 12 24 Dose fter HD 250 mg q12 Ampicillin 250 mg 2 g q6 6 6 12 12 24 Dose fter HD 250 mg q12 Cephlexin 250 500 mg q6 6 8 8 12 12 24 Dose fter HD 12 24 Clindmycin 150 450 mg q6 Doxycycline 100 mg q12 Erythromycin 250 500 mg q6 Metronidzole 250 500 mg q8-12 Dose fter HD Penicillin VK 500 mg q6 Tetrcycline 250 500 mg q6-12 8 12 12 24 24 Vncomycin 500 mg 1.25 g q12 1 g q12-24 1 g q24-96 1 g q4-7 dys 1 g q4-7 dys 1 g q4-7 dys Anlgesics Acetminophen 650 mg q4 4 6 8 Aspirin 650 mg q4 4 4 6 Avoid use Dose fter HD Ibuprofen 400 800 mg q8 Ketorolc 30 60 mg lod; 15 30 mg q6 100% 50% 25 50% Locl nesthetics Individulized

Adjustment of Mintennce Dose Intervls (in Hours), Totl Dose, or Timing with Dilysis for Adult Ptients in Renl Filure Drug Usul Dosge Norml Renl Function Mild Renl Filure (GRF > 50) Moderte Renl Filure (GRF 10 50) Severe Renl Filure (GRF < 10) Hemodilysis (HD) Peritonel Dilysis Codeine 30 60 mg q4-6 Meperidine 50 100 mg q3-4 Morphine 20 25 mg q4 Propoxyphene 65 mg q6-8 Nrcotics 75% 50% No dt No dt 75% 50% Avoid Avoid 75% 50% No dt Avoid Avoid Avoid Brbiturtes Pentobrbitl 30 mg q6-8 Secobrbitl 30 50 mg q6-8 Benzodizepines Midzolm Individulized 50% Dizepm 2 10 mg q6-24 Lorzepm 1 2 mg q8-12 Trizolm 0.25 0.50 mg qhs Others Dexmethsone 0.75 9.0 mg q24 Diphenhydrmine 25 mg q6-8 Prednisone 5 60 mg q24 Fluconzole 100 400 q24 50% 50% Dose fter HD 50% Acyclovir 5 10 mg/kg q8 q12-24 50% q24 Dose fter HD 50% q24 No djustment needed.adpted from Aronoff GR et l. Drugs Prescribing in Renl Filure: Dosing Guidelines for Adults, 4th ed. 1999. Americn College of Physicins. Phildelphi, PA.